| 2181 |
DELANZ CAPSULE 30 MG |
DEXLANSOPRAZOLE PELLETS EQ.TO DEXLANSOPRAZOLE 30 MG |
CAPSULES |
ALU-ALU BLISTER |
INDICATED IN ADULTS FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS FOR UP TO EIGHT WEEKS, IN ADULTS TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN FOR UP TO SIX MONTHS, FOR THE TREATMENT OF HEARTBUTN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE FOR 4 WEEKS |
NULL |
POUNSAB PHARMA CO.,LTD |
THE SEARLE COMPANY LIMITED |
PAKISTAN |
CERTIFICATE RELEASED |
05 I 5506/23 |
09-MAY-2023 |
08-MAY-2026 |
View |
| 2182 |
DELANZ CAPSULE 60 MG |
DEXLANSOPRAZOLE PELLETS EQ.TO DEXLANSOPRAZOLE 60 MG |
CAPSULES |
ALU-ALU BLISTER |
INDICATED IN ADULTS FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS FOR UP TO EIGHT WEEKS, IN ADULTS TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN FOR UP TO SIX MONTHS, FOR THE TREATMENT OF HEARTBUTN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE FOR 4 WEEKS |
NULL |
POUNSAB PHARMA CO.,LTD |
THE SEARLE COMPANY LIMITED |
PAKISTAN |
CERTIFICATE RELEASED |
05 I 5507/23 |
09-MAY-2023 |
08-MAY-2026 |
View |
| 2183 |
EFIME 100 |
CEFIXIME TRIHYDRATE USP EQ.TO CEFIXIME ANHYDROUS 100 MG/5 ML |
ORAL SUSPENSION |
BOTTLE |
TREATMENT OF BACTERIAL INFECTIONS WHEN CAUSED BY SUSCEPTIBLE ORGANISMS: ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS, COMMUNITY-ACQUIRED PNEUMONIA, ENT INFECTION (OTITIS MEDIA, SINUSITIS, TONSILLITIS, PHARYNGITIS, LARYNGITIS), UNCOMPLICATED LOWER URINARY TRACT INFECTION INCLUDING GONOCOCCAL URETHRITIS, UNCOMPLICATED PYELONEPHRITIS. |
NULL |
POUNSAB PHARMA CO.,LTD |
BAROQUE PHARMACEUTICALS PVT LTD. |
INDIA |
CERTIFICATE RELEASED |
02 I 4021/15 |
07-JUL-2025 |
06-JUL-2030 |
View |
| 2184 |
EFIME-200 |
CEFIXIME TRIHYDRATE EQ.TO CEFIXIME ANHYDROUS 200 MG |
DISPERSIBLE TABLET |
ALU-ALU BLISTER |
TREATMENT OF BACTERIAL INFECTIONS WHEN CAUSED BY SUSCEPTIBLE ORGANISMS: UPPER AND LOWER RESPIRATORY TRACT INFECTION (OTITIS MEDIA, BRONCHITIS), URINARY TRACT INFECTION (CYSTITIS, CYSTOURETHRITIS, UNCOMPLICATED PYELONEPHRITIS). |
NULL |
POUNSAB PHARMA CO.,LTD |
BAROQUE PHARMACEUTICALS PVT LTD. |
INDIA |
CERTIFICATE RELEASED |
02 I 4020/15 |
07-JUL-2025 |
06-JUL-2030 |
View |
| 2185 |
EZIUM |
ESOMEPRAZOLE MAGNESIUM 22.5 % PELLETS EQ.TO ESOMEPRAZOLE 40 MG |
CAPSULE |
ALU-BLISTER |
GASTROESOPHAGEAL REFLUX DISEASE, TREATMENT OF EROSIVE REFLUX ESOPHAGITIS, LONG TERM MANAGEMENT OF PATIENTS WITH HEALED ESOPHAGITIS TO PREVENT RELAPSE, SYMPTOMATIC TREATMENT OF GERD WITHOUT ESOPHAGITIS. AS A TRIPLE THERAPY(ESOMEPRAZOLE + AMOXICILLIN +CLARITHROMYCIN) FOR THE ERADICATION OF HELICOBACTER PYLORI, HEALING OF DUODENAL ASSOCIATED WITH H.PYLORI INFECTION, PREVENTION OF RELAPSE OF PEPTIC ULCERS IN PATIENTS WITH H.PYLORI, ASSOCIATED ULCERS |
NULL |
POUNSAB PHARMA CO.,LTD |
THE SEARLE COMPANY LIMITED |
PAKISTAN |
CERTIFICATE RELEASED |
02 I 4902/20 |
19-Apr-2023 |
18-Apr-2026 |
View |
| 2186 |
EZIUM |
ESOMEPRAZOLE MAGNESIUM 22.5 % PELLETS EQ.TO ESOMEPRAZOLE 20 MG |
CAPSULE |
ALU-BLISTER |
GASTROESOPHAGEAL REFLUX DISEASE, TREATMENT OF EROSIVE REFLUX ESOPHAGITIS, LONG TERM MANAGEMENT OF PATIENTS WITH HEALED ESOPHAGITIS TO PREVENT RELAPSE, SYMPTOMATIC TREATMENT OF GERD WITHOUT ESOPHAGITIS. AS A TRIPLE THERAPY(ESOMEPRAZOLE + AMOXICILLIN +CLARITHROMYCIN) FOR THE ERADICATION OF HELICOBACTER PYLORI, HEALING OF DUODENAL ASSOCIATED WITH H.PYLORI INFECTION, PREVENTION OF RELAPSE OF PEPTIC ULCERS IN PATIENTS WITH H.PYLORI, ASSOCIATED ULCERS |
NULL |
POUNSAB PHARMA CO.,LTD |
THE SEARLE COMPANY LIMITED |
PAKISTAN |
CERTIFICATE RELEASED |
02 I 4901/20 |
19-Apr-2023 |
18-Apr-2026 |
View |
| 2187 |
FIMABUTE |
CEFIXIME TRIHYDRATE EQ.TO ANHYDROUS CEFIXIME 200 MG |
FILM-COATED TABLETS |
STRIP |
UPPER RESPIRATORY TRACT INFECTION, LOWER REAPIRATORY TRACT INFECTION, URINARY TRACT INFECTIONS |
NULL |
POUNSAB PHARMA CO.,LTD |
BRAWN LABORATORIES LIMITED |
INDIA |
CERTIFICATE RELEASED |
10 I 4595/18 |
06-DEC-2022 |
05-DEC-2025 |
View |
| 2188 |
FIMABUTE 400 |
CEFIXIME TRIHYDRATE EQ.TO ANHYDROUS CEFIXIME 400 MG |
FILM-COATED TABLETS |
STRIP |
LOWER AND UPPER RESPIRATORY TRACT INFECTION AND URINARY TRACT INFECTION. |
NULL |
POUNSAB PHARMA CO.,LTD |
BRAWN LABORATORIES LIMITED |
INDIA |
CERTIFICATE RELEASED |
10 I 4596/18 |
06-DEC-2022 |
05-DEC-2025 |
View |
| 2189 |
FOPRACY |
TOBRAMYCIN USP 0.3%W/V |
OPHTHALMIC SOLUTION |
BOTTLE |
TREATMENT OF SUPERFICIAL BACTERIAL INFECTIONS OF THE EYE, SUCH AS CONJUNCTIVITIS, CAUSED BY TOBRAMYCIN SUSXEPTIBLE/SUSPECTED SUSCEPTIBLE BACTERIA IN ADULTS AND CHILDREN AGED 1 YEAR AND OLDER |
NULL |
POUNSAB PHARMA CO.,LTD |
BRAWN LABORATORIES LIMITED |
INDIA |
CERTIFICATE RELEASED |
04 I 4695/19 |
06-DEC-2022 |
05-DEC-2025 |
View |
| 2190 |
GRAVINATE |
DIMENHYDRINATE 50 MG/ML |
SOLUTION FOR INJECTION |
AMPOULES |
FOR PREVENTION AND TREATMENT OF NAUSEA, VOMITING OR VERTIGO OF MOTION SICKNESS |
NULL |
POUNSAB PHARMA CO.,LTD |
THE SEARLE CO.,LTD |
PAKISTAN |
CERTIFICATE RELEASED |
02 I 5890/25 |
2025-02-24 |
2030-02-23 |
View |
